-
Featured Authors
Archive
- May 2013 (2)
- April 2013 (5)
- March 2013 (2)
- February 2013 (4)
- January 2013 (1)
- December 2012 (2)
- November 2012 (3)
- October 2012 (3)
- September 2012 (3)
- August 2012 (5)
- July 2012 (4)
- June 2012 (7)
- May 2012 (5)
- April 2012 (3)
- March 2012 (4)
- February 2012 (6)
- January 2012 (2)
- December 2011 (2)
- November 2011 (3)
- October 2011 (3)
- September 2011 (5)
- August 2011 (4)
- July 2011 (8)
- June 2011 (16)
- May 2011 (8)
- April 2011 (9)
- March 2011 (14)
- February 2011 (9)
- January 2011 (15)
- December 2010 (7)
- November 2010 (6)
- October 2010 (4)
- June 2010 (1)
- May 2010 (4)
- April 2010 (14)
- March 2010 (4)
- January 2010 (5)
- November 2009 (3)
- October 2009 (1)
- August 2009 (6)
- July 2009 (9)
- June 2009 (9)
- May 2009 (8)
- April 2009 (9)
- March 2009 (9)
- February 2009 (3)
- January 2009 (1)
- November 2008 (1)
Category Archives: Patently BIOtech
IP Creates Jobs for America
By Mark Elliot, Executive Vice President, U.S. Chamber of Commerce’s Global Intellectual Property Center In May, the Global Intellectual Property Center (GIPC) was proud to unveil the results of our state intellectual property (IP) jobs research, which has been a year in the making. The study, IP Creates Jobs for America, provides real, tangible evidence that the economic benefits of IP are broad and far-reaching. In looking at a variety of government data on intellectual Read More >
Mayo v. Prometheus: Thought Leaders Express Concern and Evaluate the Impact
The Mayo v. Prometheus event hosted at George Washington School of Law with the Biotechnology Industry Organization created an opportunity for a panel of thought leaders to distill meaning from the case, the impact on personalized medicine, and possible solutions to the Court created problem.* Is the decision a game-changer? Judge Paul R. Michel, former Chief Judge of the Court of Appeals for the Federal Circuit handling patent cases, concluded that the Mayo v. Prometheus Read More >
Patent-Eligible Subject Matter after Mayo v. Prometheus: Exploring the Path Forward
Patent-Eligible Subject Matter after Mayo v. Prometheus: Exploring the Path Forward is a public round-table event hosted by the Biotechnology Industry Organization and the George Washington University Law School. Guest speakers at the round-table will discuss implementation of the Prometheus decision in patent prosecution practice, in examination guidance in the United States Patent Office, and in patent litigation. Speakers will also discuss the implications of the decision on personalized medicine and possible ways forward. Speakers include: The Hon. Paul Read More >
American Invents Act Strategies Highlighted at the IPCC Conference
By David Saravitz, Alston + Bird Day 2 of the 2012 BIO Intellectual Property Counsels’ Committee (IPCC) Spring Conference kicked off with a panel on the America Invents Act (AIA). The panel focused on how practitioners and the U.S. Patent & Trademark Office (USPTO) are dealing with various provisions of this new patent act. Mr. Ira Finkelstein, Senior Patent Counsel with Baxter Healthcare, led off the session initially discussing the first-inventor-to-file provision of the AIA (§ Read More >
Biotech Patent Case Law Updates at the IPCC
By John W. Cox, Counsel at Alston+Bird LLP The Spring 2012 BIO Intellectual Property Counsels’ Committee (IPCC) Conference, held in Austin, Texas, provided an excellent forum for intellectual property (IP) practitioners in the biotech industry to socialize, network, and participate in panel discussions focusing on the dynamic developments in the patent laws. The conference began for the general participants over margaritas and Tex-Mex fare, where attendees were already discussing recent Supreme Court and Federal Circuit decisions Read More >
